Correlation of clinical and immunological data in a metastatic melanoma patient with heterogeneous tumor responses to ipilimumab therapy.
Melanoma patients treated with anti-CTLA-4 have shown a range of anti-tumor responses. In this report, we describe the response of a single patient to anti-CTLA-4, with individual lesions disappearing, others stabilizing, and others progressing. These responses can be viewed as a clear manifestation of cancer immunoediting and its three phases of elimination, equilibrium and escape, with each tumor in this patient being at a discrete stage in the process. The patient's course and associated immunological monitoring and other laboratory data are presented in an immunogram, a way to visualize temporal associations between the multiple clinical and laboratory parameters.
Yuan
Jianda
J
Ludwig Center for Cancer Immunotherapy, Immunology Program, Sloan-Kettering Institute, New York, NY 10065, USA.
Page
David B
DB
Ku
Geoffrey Y
GY
Li
Yanyun
Y
Mu
Zhenyu
Z
Ariyan
Charlotte
C
Gallardo
Humilidad F
HF
Roman
Ruth-Ann
RA
Heine
Agnes I
AI
Terzulli
Stephanie L
SL
Ritter
Erika
E
Gnjatic
Sacha
S
Ritter
Gerd
G
Jungbluth
Achim A
AA
Allison
James P
JP
Old
Lloyd J
LJ
Wolchok
Jedd D
JD
D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D002452:Cell Count; D002469:Cell Separation; D005260:Female; D005434:Flow Cytometry; D006801:Humans; D007150:Immunohistochemistry; D000074324:Ipilimumab; D008214:Lymphocytes / Q000187:drug effects; D008545:Melanoma / Q000188:drug therapy* / Q000276:immunology / Q000556:secondary*; D008875:Middle Aged; D012878:Skin Neoplasms / Q000188:drug therapy* / Q000276:immunology / Q000473:pathology*
D000911:Antibodies, Monoclonal; D000970:Antineoplastic Agents; D000074324:Ipilimumab